Mark Johnson oversees all clinical trials at OncoVanta Therapeutics, ensuring the safety and efficacy of groundbreaking TCR-T therapies. With a background in clinical pharmacology and years of experience in trial management, Mark plays a crucial role in bridging the gap between research and patient care. His analytical skills and attention to detail help streamline processes, making clinical research more efficient. Mark is committed to patient advocacy, ensuring that the voice of those affected by cancer remains central to the development of new therapies. He believes in a collaborative approach to research and development.